Skip to main content

BIAF

Stock
Health Care
Diagnostics & Research

Performance overview

BIAF Price
Price Chart

Forward-looking statistics

Beta
0.38
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees38
Market cap$26.1M

Fundamentals

Enterprise value$8.6M
Revenue$8.8M
Revenue per employee—
Profit margin-110.55%
Debt to equity92.48

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.71
Dividend per share—
Revenue per share$0.64
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth-11.0
Credit+2.0
Liquidity+6.0
Inflation-7.1
Commodities+1.9
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio-0.45
Price to sales0.88
P/E Ratio-0.45
Enterprise Value to Revenue0.97
Price to book3.36

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.

Zacks Investment Research (May 20, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free